68Gallium-PET (68Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a 68Ge/68Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of 68Ga permits imaging applications with sufficient radioactivity while maintaining patient dose to an acceptable level. Furthermore, due to superior resolution, 68Ga-PET agents have the ability to replace current SPECT agents in many applications. This article outlines the upcoming agents and challenges faced during the translational development of 68Ga agents.

, ,
doi.org/10.1016/j.apradiso.2012.10.014, hdl.handle.net/1765/60642
Applied Radiation and Isotopes
Department of Nuclear Medicine

Smith, D., Breeman, W., & Sims-Mourtada, J. (2013). The untapped potential of Gallium 68-PET: The next wave of 68Ga-agents. Applied Radiation and Isotopes, 76, 14–23. doi:10.1016/j.apradiso.2012.10.014